PRAME Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of PRAME Antibodies for research focused on understanding PRAME (Preferentially Expressed Antigen in Melanoma). PRAME Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). PRAME functions as a cancer/testis antigen with a significant role in tumor immune evasion and shows associations with various malignancies, including melanoma and leukemia. Expression of PRAME is typically restricted to the testis, making it an attractive target for cancer immunotherapy research. Investigating PRAME can reveal important insights into tumor biology and potential therapeutic approaches. Current research indicates PRAME may serve as a biomarker for disease progression and treatment response in certain cancers. Ongoing studies continue to uncover new functions and regulatory mechanisms of PRAME in cancer development. Understanding PRAME's molecular interactions helps identify novel therapeutic targets and strategies. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of PRAME and its implications in cancer biology.